Related Experiment Video
Updated: Jun 21, 2026
11:02
Presynaptically Silent Synapses Studied with Light Microscopy
Published on: January 4, 2010
Serotonin targets inhibitory synapses to induce modulation of network functions
Till Manzke1, Mathias Dutschmann, Gerald Schlaf
1Department of Neuro- and Sensory Physiology, University of Göttingen, , 37073 Göttingen, Germany.
Summary
Serotonin (5-HT) receptor 1A (5-HT1AR) activation enhances glycinergic inhibition in the respiratory network. This stabilizes breathing rhythm, counteracting opiate-induced respiratory depression.
Area of Science:
- Neuroscience
- Pharmacology
- Respiratory Physiology
Background:
- Serotonin (5-HT) is a neuromodulator influencing the central nervous system.
- Neuronal network responses to 5-HT are complex due to heterogeneous serotonin receptor (5-HTR) expression.
- Predicting network-level effects of global 5-HT action remains challenging.
Purpose of the Study:
- To investigate the cellular effects of serotonin (5-HT) on neuronal networks.
- To elucidate the role of serotonin 5-HT1A receptors (5-HT1AR) in modulating respiratory network function.
- To determine if 5-HT1AR activation can mitigate opiate-induced respiratory depression.
Main Methods:
- Utilized the respiratory network as a model system for reciprocal synaptic inhibition.
- Investigated the effects of 5-HT1AR modulation on glycinergic synapses.
- Analyzed changes in network reorganization and motor output.
Main Results:
- 5-HT1AR modulation primarily impacts inhibition via glycinergic synapses.
- Potentiation of glycinergic inhibition in both excitatory and inhibitory neurons leads to network reorganization.
- Observed a characteristic change in motor output, stabilizing respiratory rhythmicity.
Conclusions:
- 5-HT1A receptor activation reorganizes neuronal networks by potentiating glycinergic inhibition.
- This mechanism stabilizes respiratory rhythm, offering a potential countermeasure to opiate-induced respiratory depression.
- 5-HT1AR activation shows promise in stabilizing breathing during pain management with opiates.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Excitatory and Inhibitory Effects of Neurotransmitters
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of specific...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...